Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML

2021 . Jaramillo, Sonia | Krisam, Johannes | Le Cornet, Lucian | Kratzmann, Markus | Baumann, Lukas | Sauer, Tim | Crysandt, Martina | Rank, Andreas | Behringer, Dirk | Teichmann, Lino | Görner, Martin | Trappe, Ralf-Ulrich | Röllig, Christoph | Krause, Stefan | Hanoun, Maher | Hopfer, Olaf | Held, Gerhard | Buske, Sebastian | Fransecky, Lars | Kayser, Sabine | Schliemann, Christoph | Schaefer-Eckart, Kerstin | Al-Fareh, Yousef | Schubert, Jörg | Geer, Thomas | Kaufmann, Martin | Brecht, Arne | Niemann, Dirk | Kieser, Meinhard | Bornhäuser, Martin | Platzbecker, Uwe | Serve, Hubert | Baldus, Claudia D. | Müller-Tidow, Carsten | Schlenk, Richard F.